Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

September 2021; 8 (5) ArticleOpen Access

Interleukin 8, a Biomarker to Differentiate Guillain-Barré Syndrome From CIDP

Gautier Breville, View ORCID ProfileAgustina M. Lascano, Pascale Roux-Lombard, Nicolas Vuilleumier, Patrice H. Lalive
First published June 17, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001031
Gautier Breville
From the Department of Neurosciences (G.B., A.M.L., P.H.L.), Division of Neurology, Geneva University Hospitals and University of Geneva, Faculty of Medicine, Switzerland; Department of Diagnostic, Division of Laboratory Medicine (P.R.-L., N.V.), Geneva University Hospitals, Switzerland; Department of Medicine (P.R.-L., P.H.L.), Division of Immunology and Allergy (P.R.-L.), Geneva University Hospitals, Switzerland; and Department of Pathology and Immunology (P.H.L.), Faculty of Medicine, University of Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agustina M. Lascano
From the Department of Neurosciences (G.B., A.M.L., P.H.L.), Division of Neurology, Geneva University Hospitals and University of Geneva, Faculty of Medicine, Switzerland; Department of Diagnostic, Division of Laboratory Medicine (P.R.-L., N.V.), Geneva University Hospitals, Switzerland; Department of Medicine (P.R.-L., P.H.L.), Division of Immunology and Allergy (P.R.-L.), Geneva University Hospitals, Switzerland; and Department of Pathology and Immunology (P.H.L.), Faculty of Medicine, University of Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Agustina M. Lascano
Pascale Roux-Lombard
From the Department of Neurosciences (G.B., A.M.L., P.H.L.), Division of Neurology, Geneva University Hospitals and University of Geneva, Faculty of Medicine, Switzerland; Department of Diagnostic, Division of Laboratory Medicine (P.R.-L., N.V.), Geneva University Hospitals, Switzerland; Department of Medicine (P.R.-L., P.H.L.), Division of Immunology and Allergy (P.R.-L.), Geneva University Hospitals, Switzerland; and Department of Pathology and Immunology (P.H.L.), Faculty of Medicine, University of Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Vuilleumier
From the Department of Neurosciences (G.B., A.M.L., P.H.L.), Division of Neurology, Geneva University Hospitals and University of Geneva, Faculty of Medicine, Switzerland; Department of Diagnostic, Division of Laboratory Medicine (P.R.-L., N.V.), Geneva University Hospitals, Switzerland; Department of Medicine (P.R.-L., P.H.L.), Division of Immunology and Allergy (P.R.-L.), Geneva University Hospitals, Switzerland; and Department of Pathology and Immunology (P.H.L.), Faculty of Medicine, University of Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrice H. Lalive
From the Department of Neurosciences (G.B., A.M.L., P.H.L.), Division of Neurology, Geneva University Hospitals and University of Geneva, Faculty of Medicine, Switzerland; Department of Diagnostic, Division of Laboratory Medicine (P.R.-L., N.V.), Geneva University Hospitals, Switzerland; Department of Medicine (P.R.-L., P.H.L.), Division of Immunology and Allergy (P.R.-L.), Geneva University Hospitals, Switzerland; and Department of Pathology and Immunology (P.H.L.), Faculty of Medicine, University of Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: agustina.lascano@hcuge.ch
Full PDF
Citation
Interleukin 8, a Biomarker to Differentiate Guillain-Barré Syndrome From CIDP
Gautier Breville, Agustina M. Lascano, Pascale Roux-Lombard, Nicolas Vuilleumier, Patrice H. Lalive
Neurol Neuroimmunol Neuroinflamm Sep 2021, 8 (5) e1031; DOI: 10.1212/NXI.0000000000001031

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
1039

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Abstract

Objective To determine whether CSF interleukin 8 (IL-8) concentration can help to distinguish Guillain-Barré syndrome (GBS) from chronic inflammatory demyelinating polyneuropathy (CIDP) at the initial stage of the disease.

Methods We performed retrospective immunoassay of IL-8 in CSF, collected at the University Hospitals of Geneva between 2010 and 2018, from patients diagnosed with GBS (n = 45) and with CIDP (n = 30) according to the Brighton and European Federation of Neurological Societies/Peripheral Nerve Society criteria by a physician blinded to biological results.

Results CSF IL-8 was higher in GBS (median: 83.9 pg/mL) than in CIDP (41.0 pg/mL) (p < 0.001). Receiver operating characteristic analyses indicated that the optimal IL-8 cutoff was 70 pg/mL. Above this value, patients were more likely to present GBS than CIDP (specificity 96.7%, sensitivity 64.4%, positive predictive value [PPV] 96.7%, and negative predictive value [NPV] 64.4%). Among GBS subcategories, IL-8 was higher in acute inflammatory demyelinating polyneuropathy (AIDP, median: 101.8 pg/mL) than in other GBS variants (median: 53.7 pg/mL). In addition, with CSF IL-8 above 70 pg/mL, patients were more likely to present AIDP than acute-onset CIDP (p < 0.001; specificity 100%, sensitivity 78.8%, PPV 100%, and NPV 46.2%) or other CIDP with nonacute presentation (p < 0.0001; specificity 95.8%, sensitivity 78.8%, PPV 96.3%, and NPV 76.7%).

Conclusion CSF IL-8 levels can help to differentiate AIDP variant of GBS from CIDP, including acute-onset CIDP, with high specificity and PPV. This may improve early and appropriate treatment.

Classification of Evidence This study provides Class II evidence that CSF IL-8 levels accurately distinguish patients with GBS from those with CIDP.

Glossary

CIDP=
chronic inflammatory demyelinating polyneuropathy;
GBS=
Guillain-Barré syndrome;
HUG=
Geneva University Hospitals;
IL-8=
interleukin 8;
IQR=
interquartile range;
NPV=
negative predictive value;
PPV=
positive predictive value;
ROC=
receiver operating characteristic

Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are heterogeneous neuropathic diseases caused by an immune-mediated inflammatory process, with different temporal evolution.1,2 In GBS, symptoms develop over 4 weeks before reaching a steady state,1 whereas CIDP has continuous clinical worsening for more than 8 weeks.2,3 Although CIDP usually has progressive onset, a study reported that 16% of patients with CIDP have acute symptoms with a nadir within 8 weeks from the onset of disease, followed by a chronic course. These patients were defined as acute-onset CIDP.4

Both GBS and CIDP diagnostic strategies rely on clinical, electroneuromyography (ENMG), and CSF findings, namely albuminocytologic dissociation.1,-,3 Although CIDP differs from GBS in its time course, disease duration, prognosis, and steroid responsiveness, no specific biomarker exists in both blood and CSF to distinguish these 2 diseases.5 Nevertheless, 2 cytokine screening–based studies—with a limited number of patients—have shown a trend of CSF interleukin 8 (IL-8) elevation in GBS more than in CIDP.6,7 IL-8 is a proinflammatory chemokine primarily secreted by circulating monocytes and local macrophages. It plays a crucial role in the inflammatory cascade by inducing chemotaxis gradient, migration, and oxidative burst.8

In practice, although GBS and CIDP are usually distinguishable in most of the cases, overlapping clinical and paraclinical features may occur, especially when CIDP begins with acute onset, which can mimic GBS at early stages.4 This study aims to evaluate the potential use of CSF IL-8 as a biomarker to help to differentiate GBS and CIDP at disease onset.

Methods

This study aims to determine whether CSF IL-8 concentration can help to distinguish GBS from CIDP at the initial stage of the disease. It provides Class II evidence that CSF IL-8 levels accurately distinguish patients with GBS from those with CIDP. The protocol was approved by the Geneva University Hospitals (HUG) Medical Ethical board (authorization #2019-01210), and the requirement for patient consent was waived.

Patients

This study is based on a cohort of 75 patients diagnosed with GBS (n = 45) or CIDP (n = 30) between 2010 and 2018 and followed in the Neurology Clinics of the HUG. Diagnoses were established according to Brighton9 and European Federation of Neurological Societies/Peripheral Nerve Society criteria3 by a physician blinded to biological results (A.M.L.). Baseline demographic, clinical, and biological patients' characteristics are summarized in table e-1, links.lww.com/NXI/A505. Disease duration was defined as the time between symptom onset and lumbar puncture. Exclusion criteria were age <18 years, active systemic autoimmune/tumoral diseases at the time of lumbar puncture, no ENMG, and follow-up <1 year.

Determination of IL-8 Levels in the CSF

IL-8 was measured using commercially available multiplex bead immunoassays (Fluorokine MAP Multiplex Human Cytokine Panel, R&D Systems).

Statistical Analysis

Because of the asymmetric data distribution of CSF IL-8 levels, we applied nonparametric tests for statistical analysis. We used the Wilcoxon-Mann-Whitney test for the distribution analysis for the head-to-head comparisons. A p value <0.05 was considered statistically significant. We used receiver operating characteristic (ROC) curve analysis to determine the power (sensitivity and specificity) of CSF IL-8 as a diagnostic marker for GBS.

Data Availability

The corresponding author is in possession of detailed methods and results of this study, which are available on request.

Results

The median CSF IL-8 concentration was 83.9 pg/mL in the GBS group (n = 45; interquartile range [IQR] 64.4 [118.9–54.5]) compared with 41.0 pg/mL in the CIDP group (n = 30; IQR 17.3 [53.2–35.9]) (p value <0.001, figure 1A). ROC curves, to determine IL-8 diagnostic accuracy for GBS, indicated that the IL-8 area under the curve was of 0.86 (95% CI: 0.77–0.94) (p < 0.001, figure 1B). Using the Youden index, the optimal cutoff value was set at 70 pg/mL, beyond which IL-8 was considered as positive. This cutoff yields a specificity of 96.7% and a sensitivity of 64.4%, with a positive predictive value (PPV) of 96.7% and a negative predictive value (NPV) of 64.4%, for the diagnosis of GBS instead of CIDP. Additional serum and CSF analyses are summarized in table 1. Both groups showed similar levels of CSF white blood cells, abnormal protein levels, and albumin quotient.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Distribution of CSF IL-8 Levels and ROC Curve

(A) Distribution of CSF IL-8 levels between patients with GBS and CIDP. Box-and-whisker plot (median, first and third quartiles, and range) of the distribution of CSF IL-8 levels between GBS (n = 45) and CIDP (n = 30) patient groups. Compared with CIDP (median: 41.0 pg/mL; IQR 17.3 [53.2–35.9]), CSF IL-8 was significantly increased in GBS (median: 83.9 pg/mL; IQR 64.4 [118.9–54.5]) (p < 0.001). The CSF IL-8 levels of all individual patients were measured using multiplex bead immunoassays. (B) IL-8 ROC curves. The ROC curve was calculated for optimal cutoff values. The AUC was calculated at 0.856 (0.771–0.941). The optimal cutoff value of CSF IL-8 to discriminate GBS from CIDP was set at 70 pg/mL for a sensitivity of 64.4% and a specificity of 96.7%. AUC = area under the curve; CIDP = chronic inflammatory demyelinating polyneuropathy; GBS = Guillain-Barré syndrome; IL-8 = interleukin 8; ROC = receiver operating characteristic. ***p < 0.001.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1

IL-8 Results and Other Biological Characteristics of Patients With GBS and CIDP (n = 75)

We next performed a subanalysis to test the different GBS vs CIDP subgroups (figure 2). Most of the IL-8–positive patients with GBS were diagnosed with acute inflammatory demyelinating polyneuropathy (AIDP) (n = 33; median: 101.8 pg/mL, IQR 74.2 [146.6–72.4]). Other GBS variants, including acute motor axonal neuropathy/acute motor and sensitive axonal neuropathy/MFS, showed lower IL-8 levels (n = 12; median: 53.7 pg/mL, IQR 27.4 [70.5–43.1]). Above the cutoff value of 70 pg/mL, patients were more likely to present AIDP than other GBS phenotypes (p < 0.001; specificity 75.0%, sensitivity 78.8%, PPV 89.7%, and NPV 56.3%) or CIDP (p < 0.0001; specificity 96.7%, sensitivity 78.8%, PPV 96.3%, and NPV 80.5%). With this cutoff value, IL-8 was positive in 78.8% of patients with AIDP (26/33) against 3.3% (1/30) in patients with CIDP.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 Distribution of CSF IL-8 Levels in Patient Subgroups

Box-and-whisker plot (median, first and third quartiles, and range) of the distribution of CSF IL-8 levels in patient subgroups. Among GBS subcategories, CSF IL-8 concentration was higher in AIDP (n = 33; median: 101.8 pg/mL, IQR 74.2 [146.6–72.4]) as opposed to axonal GBS phenotypes (AMAN and AMSAN) or MFS (n = 12; median: 53.7 pg/mL, IQR 27.4 [70.5–43.1]) (p < 0.001). Compared with acute-onset CIDP (n = 6; median: 38.9 pg/mL, IQR 25.2 [58.7–33.5]) and other CIDP (n = 24, median: 41.6 pg/mL; IQR 15.8 [52.1–36.3]), CSF IL-8 was significantly increased in AIDP (respectively p < 0.001 and p < 0.0001). AIDP = acute inflammatory demyelinating polyneuropathy; CIDP = chronic inflammatory demyelinating polyneuropathy; GBS = Guillain-Barré syndrome; IQR = interquartile range; IL-8 = interleukin 8. ***p < 0.001, ****p < 0.0001.

Among the 75 patients studied, 6 (8%) were diagnosed as GBS at symptom onset, based on clinical presentation and ENMG results. These patients were finally relabeled as acute-onset CIDP because of a steadily progressive evolution over 8 weeks and further ENMG results compatible with CIDP criteria.3 These patients had a lumbar puncture at symptom onset with IL-8 results <70 pg/mL (n = 6; median: 38.9 pg/mL, IQR 25.2 [58.7–33.5]). Among other CIDP without acute presentation (n = 24), IL-8 was negative except for 1 patient (70.7 pg/mL; median: 41.6 pg/mL; IQR 15.8 [52.1–36.3]). Above the cutoff value of 70 pg/mL, patients were more likely to present AIDP than acute-onset CIDP (p < 0.001; specificity 100%, sensitivity 78.8%, PPV 100%, and NPV 46.2%) or other CIDP (p < 0.0001; specificity 95.8%, sensitivity 78.8%, PPV 96.3%, and NPV 76.7%). Finally, IL-8 concentrations among GBS variants were compared with typical CIDP and atypical CIDP (European Federation of Neurological Societies/Peripheral Nerve Society criteria3) (figure e-1, links.lww.com/NXI/A504).

Discussion

This retrospective study shows that the CSF IL-8 concentration, when measured at the time of the initial diagnostic workup, is significantly increased in GBS when compared with CIDP. Our results suggest that a measurement of IL-8 with a cutoff of >70 pg/mL yields a PPV of 96% to differentiate patients with GBS from those with CIDP.

Among GBS subgroups, patients with AIDP had the most elevated IL-8 levels. AIDP and CIDP both sharing similar ENMG parameters, their distinction can be difficult at the acute phase. In this sense, CSF IL-8 appears to be a useful biomarker to differentiate AIDP from CIDP at the acute phase, with a median of 101.8 pg/mL in the AIDP group instead of 41.0 pg/mL in the CIDP group. However, it is important to emphasize that no subject had active systemic autoimmune/tumoral disease.

These findings have direct clinical implications because acute-onset CIDP may mimic GBS at early stages. In our cohort, 6 patients (8%) were misdiagnosed at disease onset as having GBS instead of CIDP.4 The diagnostic adjustment of acute-onset CIDP was made based on the clinical evolution and repeated ENMG. Of interest, all patients had retrospectively negative CSF IL-8. Despite the low number of patients with acute CIDP analyzed, the IL-8 difference with AIDP remains highly significant (p < 0.001). Nevertheless, these results will have to be confirmed with other studies before CSF IL-8 is validated as a routine test.

Improving the initial diagnosis of GBS vs CIDP may allow to better tailor the medical treatment and to prevent disease progression. IVIg and plasmapheresis are indicated in both diseases, but steroids are effective only for CIDP2 and may worsen GBS outcome.1 In nonacute CIDP, clinical examination and evolution in time as well as ENMG are sufficient to rule out GBS or AIDP. Thus, CSF IL-8 testing could be performed during the acute phase of investigation to permit a more rapid discriminatory diagnosis in combination with the clinical and paraclinical parameters. Cytokines, such as IL-8, can be easily measured in most university hospital laboratories and in some private laboratories with a routine test.

Study Funding

No targeted funding reported.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

Appendix Authors

Table

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • The Article Processing Charge was funded by the authors.

  • Received January 12, 2021.
  • Accepted in final form April 14, 2021.
  • Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Yuki N,
    2. Hartung HP
    . Guillain-Barré syndrome. N Engl J Med. 2012;366(24):2294-2304.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Dalakas MC
    . Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol. 2011;7(9):507-517.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Van den Bergh PY,
    2. Hadden RD,
    3. Bouche P, et al
    . European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. Eur J Neurol. 2010;17(3):356-363.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Ruts L,
    2. Drenthen J,
    3. Jacobs BC,
    4. van Doorn PA
    . Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74(21):1680-1686.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Illes Z,
    2. Blaabjerg M
    . Cerebrospinal fluid findings in Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathies. Handb Clin Neurol. 2017;146:125-138.
    OpenUrlPubMed
  6. 6.↵
    1. Sainaghi PP,
    2. Collimedaglia L,
    3. Alciato F, et al
    . The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barré syndrome from chronic inflammatory demyelinating polyneuropathy. Cytokine. 2010;51(12):138-143.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Breville G,
    2. Lascano AM,
    3. Roux-Lombard P,
    4. Lalive PH
    . IL-8 as a potential biomarker in Guillain-Barre Syndrome. Eur Cytokine Netw. 2019;30(4):130-134.
    OpenUrl
  8. 8.↵
    1. Ha H,
    2. Debnath B,
    3. Neamati N
    . Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics. 2017;7(6):1543-1588.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Fokke C,
    2. Van Den Berg B,
    3. Drenthen J,
    4. Walgaard C,
    5. Van Doorn PA,
    6. Jacobs BC
    . Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(pt 1):33-43.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • Glossary
    • Methods
    • Results
    • Discussion
    • Study Funding
    • Disclosure
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • Autoimmune diseases
  • Guillain-Barre syndrome
  • Chronic inflammatory demyelinating polyneuropathy

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise